1 |
Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B. Adriamycin sensitizes the adriamycinresistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)-mediated apoptosis. Clin Cancer Res. 2001 ; 7(12) : 3874-3883.
|
2 |
Tillman DM, Izeradjene K, Szucs KS, Douglas L, Houghton JA. Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res. 2003 ; 63(16) : 5118-5125.
|
3 |
Rothe M, Sarma V, Dixit VM, Goeddel DV. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science. 1995 ; 269(5229) : 1424-1427.
DOI
ScienceOn
|
4 |
Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell. 1994 ; 78(4) : 681-692.
DOI
ScienceOn
|
5 |
Hua F, Cornejo MG, Cardone MH, Stokes CL, Lauffenburger DA. Effects of Bcl-2 levels on Fas signaling-induced Caspase-3 activation: molecular genetic tests of computational model predictions, J Immunol vol. 2005 ; 175(2) : 985-995
DOI
|
6 |
Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992 ; 10 : 411-452.
DOI
ScienceOn
|
7 |
Nagata S. Apoptosis by death factor. Cell. 1997 ; 88(3) : 355-365.
DOI
ScienceOn
|
8 |
Marsters S, Sheridan J, Donahue C et al. Apo3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-B. Curr Biol. 1996 ; 6(12) : 1669-1676.
DOI
ScienceOn
|
9 |
Chinnaiyan AM, O'ourke K, Yu GL et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996 ; 274(5289) : 990-992.
DOI
ScienceOn
|
10 |
Kitson J, Raven T, Jiang YP et al. A deathdomain- containing receptor that mediates apoptosis. Nature. 1996 ; 384(6607) : 372-375.
DOI
ScienceOn
|
11 |
Bodmer JL, Burns K, Schneider P et al. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis receptor 1 and Fas(Apo-1/CD95). Immunity. 1997 ; 6(1) : 79-88.
DOI
ScienceOn
|
12 |
Screaton G, Xu X, Olsen A et al. LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc Natl Acad Sci USA 1997 ; 94(9) : 4615-4619.
DOI
|
13 |
Golstein P. Cell death: TRAIL and its receptors. Curr Biol. 1997 ; 7(12) : R750-R753.
DOI
ScienceOn
|
14 |
Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2ligand/tumor necrosis factorrelated apoptosis-inducing ligand and CPT-11. Cancer Res. 2003 ; 63(15) : 4713-4723.
|
15 |
Shankar S, Singh TR, Chen X, Thakkar H, Firnin J, Srivastava RK. The sequential treatment with ionizing radiation followed by TRAIL/ Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int J Oncol. 2004 ; 24(5) : 1133-1140.
|
16 |
Sheridan JP, Marsters SA, Pitti RM et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997 ; 277(5327) : 818-821.
DOI
ScienceOn
|
17 |
Hannon GJ. RNA interference. Nature. 2002 ; 418(6894) : 244-251.
DOI
ScienceOn
|
18 |
Jang MH, Shin MC, Lim S et al. Bee venom induces apoptosis and inhibits expression of cyclooxygenase-2 mRNA in human lung cancer cell line NCI-H1299. J Pharmacol Sci. 2003 ; 91(2) : 95-104.
DOI
ScienceOn
|
19 |
Huerta-Yepez S, Vega M, Jazirehi A et al. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene. 2004 ; 23(9) : 4993-5003.
DOI
ScienceOn
|
20 |
Liu S, Yu M, He Y et al. Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology. 2008 ; 47(6) : 1964-1973.
DOI
ScienceOn
|
21 |
Hengartner MO. The biochemistry of apoptosis. Nature. 2000 ; 407(6805) : 770-776.
DOI
ScienceOn
|
22 |
Reed JC. Apoptosis-regulating proteins as targets for drug discovery. Trends Mol Med. 2001 ; 7(7) : 314-319.
DOI
ScienceOn
|
23 |
Li JY, Xu ZJ, Tan MY, Su WK, Gong XG. 3-(4-(Benzo[d]thiazol-2-yl)-1-phenyl-1Hpyrazol -3-yl) phenyl acetate induced HepG2 cell apoptosis through a ROS-mediated pathway. Chem Biol Interact. 2010 ; 183(3) : 341-48.
DOI
ScienceOn
|
24 |
Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998 ; 281(5831) : 1309-1312.
DOI
ScienceOn
|
25 |
Cain K, Brown DG, Langlais C, Cohen GM. Caspase activation involves the formation of the aposome, a large(approximately 700 kDa) caspaseactivating complex. J Biol Chem. 1999 ; 274(32) : 22686-22682.
DOI
|
26 |
Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol. 1999 ; 17 : 331-7.
DOI
ScienceOn
|
27 |
Old LJ. Tumor necrosis factor. Sci Am. 1988 ; 258(5) : 59-60.
DOI
ScienceOn
|
28 |
Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994 ; 76(6) : 959-962.
DOI
ScienceOn
|
29 |
Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA, Jr and Goeddel DV. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA. 1991 ; 88(20) : 9292-9296.
DOI
ScienceOn
|
30 |
Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science. 1994 ; 264(5159) : 667-668.
DOI
|
31 |
Schutze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Kronke M. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "cidic"c sphingomyelin breakdown. Cell. 1992 ; 71(5) : 765-776.
DOI
ScienceOn
|
32 |
Laegreid A, Medvedev A, Nonstad U et al. Tumor necrosis factor receptor p75 mediates cell-specific activation of nuclear factor kappa B and induction of human cytomegalovirus enhancer. J Biol Chem. 1994 ; 269(10) : 7785-7791.
|
33 |
Mukhopadhyay A, Suttles J, Stout RD, Aggarwal BB. Genetic deletion of the tumor necrosis factor receptor p60 or p80 abrogates ligandmediated activation of nuclear factor-kappa B and of mitogen-activated protein kinases in macrophages. J Biol Chem 2001 ; 276(34) : 31906-31912.
DOI
ScienceOn
|
34 |
Grell M, Becke FM, Wajant H, Mannel DN, Scheurich P. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol. 1998 ; 28(1) : 257-263.
DOI
ScienceOn
|
35 |
Medvedev AE, Espevik T, Ranges G, Sundan A. Distinct roles of the two tumor necrosis factor(TNF) receptors in modulating TNF and lymphotoxin alpha effects. J Biol Chem. 1996 ; 271(16) : 9778-9784.
DOI
|
36 |
Zhu DM, Shi J, Liu S, Liu Y, Zheng D. HIV infection enhances TRAIL-induced cell death in macrophage by down-regulating decoy receptor expression and generation of reactive oxygen species. PLoS One. 2011 ; 6(4) : e18291.
DOI
ScienceOn
|
37 |
Elrod HA, Sun SY. Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther. 2008 ; 7(2) : 163-173.
DOI
ScienceOn
|
38 |
Yoshida T, Horinaka M, Sakai T. "Combinationoriented molecular-targeting prevention" of cancer: a model involving the combination of TRAIL and a DR5 inducer. Environ. Health Prev. Med. 2010 ; 15(4) : 203-210.
DOI
|
39 |
Inoue N, Matsuda F, Goto Y, Manabe N. Role of cell-death ligand-receptor system of granulosa cells in selective follicular atresia in porcine ovary. J Reprod Dev. 2011 ; 57(2) : 169-175.
DOI
ScienceOn
|
40 |
Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008 ; 19(3-4) : 325-331.
DOI
ScienceOn
|
41 |
Sun SY. Understanding the role of the death receptor 5/FADD/caspase-8 death signaling in cancer metastasis. Mol Cell Pharmacol. 2011 ;3(1) : 31-34.
|
42 |
Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene. 2010 ; 29(34) : 4752-4765.
DOI
ScienceOn
|
43 |
Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onsetprogression and therapy. Nat Rev Cancer. 2008 ; 8(10) : 782-798.
DOI
ScienceOn
|
44 |
Stegehuis JH, de Wilt LH, de Vries EG, Groen HJ, de Jong S, Kruyt FA. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives, Drug Resist. Updates. 2010 ; 13(1-2) : 2-5.
DOI
ScienceOn
|
45 |
Van Geelen CM, de Vries EG, de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updates. 2004 ; 7(6) : 345-358.
DOI
ScienceOn
|
46 |
Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics, Exp Opin Therapeut Targets. 2010 ; 14(10) : 1091-1108.
DOI
ScienceOn
|
47 |
Park JH, Jeong YJ, Park KK et al. Melittin suppresses PMA-induced tumor cell invasion by inhibiting NF-kappaB and AP-1-dependent MMP-9 expression. Mol Cells. 2010 ; 29(2) : 209-215.
DOI
ScienceOn
|
48 |
Jin CY, Park C, Hwang HJ et al. Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells, Mol. Nutr Food Res. 2011 ; 55(2) : 300-309.
DOI
ScienceOn
|
49 |
Lu M, Strohecker A, Chen F et al. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels, Clin. Cancer Res. 2008 ; 14(10) : 3168-3176.
DOI
ScienceOn
|
50 |
Park HJ, Lee SH, Son DJ et al. Antiarthritic effect of bee venom: inhibition of inflammation mediator generation by suppression of NFkappaB through interaction with the p50 subunit. Arthritis Rheum. 2004 ; 50(11) : 3504-3515.
DOI
ScienceOn
|
51 |
Park MH, Choi MS, Kwak DH et al. Anticancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-Κ. Prostate. 2011 ; 71(8) : 801-812.
DOI
ScienceOn
|
52 |
Ginsber RJ, Kris MK, Armstrong JG. Cancer of the lung in Principles and Practice of Oncology, 4th ed(DeVita DT Jr, Hellman S, Rosenberg SA eds). Philadelphia PA : Lippincott-Raven Publishers. 1993 ; 673-682.
|
53 |
Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin. 2008 ; 58(2) : 71-96.
DOI
ScienceOn
|
54 |
de Petris L, Crino L, Scagliotti GV et al. Treatment of advanced non-small cell lung cancer. Ann Oncol. 2006 ; 2 : 1136-1141.
|
55 |
Giaccone G. Clinical perspectives on platinum resistance. Drugs. 2000 ; 59(4) : 9-17.
|
56 |
Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Int Med. 2005 ; 258(6) : 479-517.
DOI
ScienceOn
|
57 |
Kang YJ, Kim IY, Kim EH et al. Paxilline enhances TRAIL-mediated apoptosis of glioma cells via modulation of c-FLIP, survivin and DR5. Exp Mol Med. 2011 ; 43(1) : 24-34.
DOI
|
58 |
Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005 ; 55(3) : 178-194. 71-96.
DOI
ScienceOn
|
59 |
Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst. 2000 ; 92(13) : 1042-1053.
DOI
ScienceOn
|
60 |
O'Donovan TR, O'Sullivan GC, McKenna S. Induction of autophagy by drugresistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy. 2011 ; 7(5) : 509-524.
DOI
|
61 |
Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood. 1995 ; 85(12) : 3378-3404.
|